Cognition Therapeutics, Inc.

NASDAQ:CGTX

Biotechnology

Healthcare
$0.60 -0.70%

-$0.01 today

Market cap
$57.06M
Beta
1.75
P/E (TTM)
-6.4
EPS (TTM)
-$0.22
52W Low $0.25High $3.83

Volume 0.34M

Average 1.23M

CGTX Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Cognition Therapeutics, Inc.NASDAQ: CGTX

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares of 89.19M shares rose 44.3% year over year, behind the +69.4% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.3% from the prior quarter. Over 3 fiscal years it compounded at +35.9% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +44.3% toward the trailing-twelve-month pace of +69.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
89.19M+0.3% QoQ
Last fiscal yearDec 2025
72.77M+83.2% YoY
LTMMar 2026
79.93M+69.4% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+44.3%——
1 year+83.2%——
3-year CAGR+35.9%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
72.77M USD
Year-over-year change
+83.2%
4-year CAGR
+34.5%

Weighted Avg Shares vs competitors

How CGTX compares with its peers on the latest reported figures

  • CGTX's LTM Mar 2026 weighted avg shares of 79.93M shares is the 2nd highest of the 8 companies compared; the peer median is 33.32M shares.
  • Its year-over-year change of +69.4% is the 3rd highest of 8, against a peer median of +10.4%.
  • Over three fiscal years its annual growth of +35.9% compares with a peer median of +17.9%.
CGTX Competitors Peer median
Weighted Avg Shares for CGTX and competitors
Company Period LTM YoY 3-year CAGR
IRDOpus Genetics, Inc.LTM Mar 2026406.29M +1283.9%+214.9%
CGTXCognition Therapeutics, Inc.LTM Mar 202679.93M +69.4%+35.9%
SEERSeer, Inc.LTM Mar 202656.96M -7.5%-2.7%
SPROSpero Therapeutics, Inc.LTM Mar 202656.4M +3.7%+14.2%
AGENAgenus Inc.LTM Mar 202633.32M +48.8%+28.3%
GLSIGreenwich LifeSciences, Inc.LTM Mar 202613.8M +5.4%+1.6%
SRZNSurrozen, Inc.LTM Mar 20269.29M +179.8%+47.8%
MCRBSeres Therapeutics, Inc.LTM Mar 20268.99M +10.4%+17.9%
Peer median (excluding CGTX) 33.32M+10.4%+17.9%

Competitors are the stored peer set for CGTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue0235K000
Gross Profit0(235K)000
Gross Margin—————
Research & Development18.57M30.32M37.2M41.68M37.19M
Selling, General & Admin10.03M13.23M13.53M12.29M10.61M
Operating Expenses28.6M43.32M50.72M53.97M47.8M
Depreciation & Amortization93K235K252K266K228K
EBITDA(10.73M)(21.13M)(25.51M)(33.68M)(23.25M)
EBITDA Margin—————
Operating Income(28.6M)(43.55M)(50.72M)(53.97M)(47.8M)
Operating Margin—————
Interest Income17.45M22.22M24.81M00
Interest Expense893K28K27K25K13K
Other Income / Expenses16.88M22.15M24.94M20M24.31M
Income Before Tax(11.72M)(21.4M)(25.79M)(33.97M)(23.49M)
Pre-Tax Margin—————
Income Tax Expense0(22.15M)000
Net Income(11.72M)757K(25.79M)(33.97M)(23.49M)
Net Margin—————
EPS (Basic)(0.73)(0.74)(0.86)(0.85)(0.32)
EPS (Diluted)(0.73)(0.74)(0.86)(0.85)(0.32)
Weighted Avg Shares22.23M28.99M29.99M39.73M72.77M
Weighted Avg Shares (Diluted)22.23M28.99M30.03M39.73M72.77M

Cognition Therapeutics, Inc.

NASDAQ:CGTX

Intrinsic Alpha fair value

Locked

Current Price

$0.60

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.